Under a tenth of people eligible to benefit from obesity jabs such as Wegovy have access to them, warns the global health agency as it publishes its inaugural guidance on the drugs.
With in excess of 1,000,000,000 individuals worldwide now obese, it is advocating for more widespread and fairer access to GLP-1 medication.
Per forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention.
"Our latest guidelines recognises that excess weight is a lifelong illness that can be treated with comprehensive and continuous treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are key hurdles to broad availability to the treatments that can help people shift substantial weight, notes the organization.
Weight-Loss Drug Supply Crisis
Even under the present most favorable scenario, the manufacturing of such drugs could only cover around 100 million people – less than 10% of eligible patients, per the health organization.
The guideline urges countries and companies to widen access, via strategies including patent sharing.
A patent on semaglutide – the primary component of Novo Nordisk's Wegovy – is scheduled to end in a number of countries in 2026.
The Way Obesity Jabs Function
GLP-1 drugs imitate a biological compound to slow digestion, reduce hunger and enhance the sense of being full so users eat less.
Individuals commonly begin shedding pounds after several weeks of starting on the regular doses.
Studies suggests patients may regain a significant portion after a year of stopping the treatment, as their normal food cravings resume.
To be carrying excess weight elevates your risk for contracting diseases, including type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity affects individuals in countries worldwide and was linked to millions of fatalities worldwide in 2024, per the health agency.
